Skip to main content

Wednesday's Small-Cap Winners & Losers

BladeLogic soars in its public debut.
  • Author:
  • Publish date:

Despite a few leaping tech names, small-cap stocks once again slunk behind the broad indices Wednesday.




, a data-center automation-software company, catapulted 45.2% to $24.69 after its

initial public offering

of 5 million shares, 3.94 million of which are being sold by the company itself. Underwriters have an option for another 750,000 shares.



, a Sunnyvale, Calif., semiconductor firm, jumped 13.6% despite coming in just under top- and bottom-line expectations for the fiscal first quarter, and semiconductor-equipment maker



was higher after posting a small break-even loss for the quarter ended June 30 on revenue of $46.6 million. Thomson Financial's estimates had it losing 2 cents a share, and two analysts predicted sales of $45.5 million.

Supertex shares were up $4.41 to $36.91 as Montana-based Semitool gained 13% to $10.20, each in support of the Russell 2000, which was up 0.2% to 813.07. The S&P SmallCap 600, which counts Supertex as a member, was up marginally at 426.99.

GPC Biotech


Scroll to Continue

TheStreet Recommends

was among Wednesday's

worst losers overall

, however, after a Food and Administration advisory panel

unanimously recommended

that the FDA wait for more information before approving its prostate-cancer drug satraplatin.

Shares of the Germany-based company plummeted 34.6% to $13.32 as partner

Spectrum Pharmaceuticals

(SPPI) - Get Spectrum Pharmaceuticals, Inc. Report

slid 17.1% to $3.98.



, which has some commercialization rights to the drug, gave up 1.2% to $24.32.

Targeted Genetics

(TGEN) - Get Tecogen Inc. Report

was another big health-care loser. Shares of the Seattle biotech company slid 20.5% to $2.09 after the FDA put development of its investigational inflammatory-arthritis therapy, tgAAC94, on clinical hold "as a precautionary measure ... due to the uncertainty of the cause of a serious adverse event that occurred in one subject." The compound had been in phase I/II testing.

Away from health stocks,

Jakks Pacific

(JAKK) - Get JAKKS Pacific, Inc. Report

was hurting after the Malibu, Calif., toy company whittled its second-quarter income down to $5 million, or 17 cents a share, from 22 cents a share last year. Wall Street had expected a year-over-year rise to 25 cents a share. Jakks stock was losing $4.52, or 15.1%, to $25.40.

Meanwhile, France-based telecom company



plunged more than 20% even though second-quarter income vaulted to $6.9 million (5 million euros), or 41 cents a share, compared with about a penny a share last year. Shares were losing $7.39 to $29.20.

As originally published, this story contained an error. Please see

Corrections and Clarifications.